Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) with the Contrast Agent Iohexol

Miscellaneous

This trial studies how well iohexol works in helping doctors calculate the dose of carboplatin given to patients with cancer. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Understanding how to best calculate the dose of carboplatin given to patients with cancer may help doctors learn how to improve the use of carboplatin in the future.
Miscellaneous
N/A
Brown, Alaina
NCT03997370
NRGGYNGY022

Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

Multiple Cancer Types

The purpose of the study is to assess the efficacy and safety of tisagenlecleucel in children and adolescents with relapsed / refractory B-cell non-Hodgkin lymphoma (r / r B-NHL). For pediatric patients who have r / r B-NHL, survival rates are dismal, only ~20-50% subjects are alive at 2 years with overall response rate (ORR) of 20-30% after conventional salvage chemotherapy.
Pediatric Lymphoma, Pediatrics
II
Kitko, Carrie
NCT03610724
VICCPED18169

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667 / KEYNOTE-667)

Multiple Cancer Types

This study will examine the safety and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy in children and young adults with newly diagnosed classical Hodgkin Lymphoma (cHL) who are slow early responders (SERs) to frontline chemotherapy.
Pediatric Lymphoma, Pediatrics
II
Friedman, Debra
NCT03407144
VICCPED1994

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905 / KEYNOTE-905 / EV-303)

Bladder

A global, randomized phase III study to evaluate perioperative pembrolizumab with radical cystectomy + pelvic lymph node dissection (RC+PLND) versus RC+PLND alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).
Bladder
III
Davis, Nancy
NCT03924895
VICCURO1960

Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer

Breast

This is a phase 3, multicenter, open-label, randomized active-controlled, parallel group to investigate the efficacy, safety and tolerability of intravenous balixafortide given with eribulin versus eribulin alone in the treatment of HER2 negative, Locally Recurrent or Metastatic Breast Cancer.
Breast
III
Mayer, Ingrid
NCT03786094
VICCBRE1947


Umbrella Long-Term Follow-Up Protocol

Pediatrics

Pediatrics
N/A
Friedman, Debra
NCT00736749
COGALTE05N1

Novel Gastrointestinal Cancer Markers in Tissue and Biofluids

Gastrointestinal

Gastrointestinal
N/A
Beauchamp, Robert
NCT00899626
VICCGI0283

Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMT CTN 1507)

Hematologic

This is a Phase II, single arm, multi-center trial, designed to estimate the efficacy and toxicity of haploidentical bone marrow transplantation (BMT) in patients with sickle cell disease (SCD). Based on their age and entry criteria patients are stratified into two groups: (1) children with SCD with strokes; and (2) adults with severe SCD.
Hematologic
II
Kassim, Adetola
NCT03263559
VICCNCCTT1759

A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed / Refractory Acute Myeloid Leukemia (AML)

Multiple Cancer Types

To evaluate the safety, pharmacokinetics (PK), and efficacy of ASTX660 when given alone and in combination with ASTX727 in participants with relapsed / refractory (R / R) acute myeloid leukemia (AML). The duration of the study is expected to be approximately 30 months.
Leukemia, Phase I
I
Mohan, Sanjay
NCT04155580
VICCHEMP19144

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: